Fundraising Fox
Massive Bio
New York, US · Founded 2015 · Delaware corporation · 7 known investors
Find your way into Massive Bio
Sign up to see every warm intro you have to Massive Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Massive Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
Founders & leadership
Massive Bio was founded in 2015 by Selin Kurnaz and Arturo Loaiza-Bonilla.
Investors · 7
How we know: open dataset · 500 Global portfolio 2026-08 · Not right? Tell us
How we know: Revo Capital's portfolio page · funding news · bostonrealestatetimes.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Also in the syndicate · 2
Funding
SEC filings, press & company announcements$5.1M disclosed across 2 of 3 rounds · 2019–2022
- $2.6MraisedNov 2020 · 2 sources
Revo Capital (lead), Cavendish Impact Foundation (CIF), ImpactAssets
Source ↗
▶$2.5MraisedMay 2019 · 2 investors · Other Health CareRule 506(b)
- Selin KurnazExecutive Officer
- Arturo Loaiza-BonillaDirector
- Offering amount
- $5.5M
- Amount sold
- $2.5M
- Minimum investment
- $500K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Massive Bio.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $399.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Massive Bio do?
- Massive Bio operates an AI-based platform that matches cancer patients with oncology clinical trials and provides concierge support throughout the trial process. It serves patients across the U.S., Canada, Latin America, and Europe, and works with pharma and CRO customers, patient advocacy organizations, and the National Cancer Institute's network of cancer centers.
- Who founded Massive Bio?
- Massive Bio was founded by Selin Kurnaz, Arturo Loaiza-Bonilla in 2015.
- Who are Massive Bio's investors?
- Massive Bio's investors include 500 Emerging Europe, 500 Global, Revo Capital, Bayes Ventures, e2vc.
- How much funding has Massive Bio raised?
- Massive Bio has disclosed $5.1M raised across 2 of its 3 known rounds.
- Where is Massive Bio headquartered?
- Massive Bio is headquartered in New York, US.